REGENERON PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
REGENERON PHARMACEUTICALS, INC. (REGN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value of $311.05 million as of 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue · last filed 2018-05-03
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $311.05M.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $326.68M.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $117.49M.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $7.44M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value |
|---|---|
| 2018-03-31 | $311.05M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $326.68M 10-Q · filed 2018-05-03 |
| 2017-09-30 | $117.49M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $7.44M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $17.63M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $36.41M 10-K · filed 2018-02-08 |
| 2016-09-30 | $52.79M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $104.10M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $135.21M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $23.75M 10-K · filed 2017-02-09 |
| 2015-09-30 | $30.28M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $7.60M 10-Q · filed 2015-08-04 |
| 2015-03-31 | $4.14M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $0.00 10-K · filed 2016-02-11 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-04 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-05 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-08 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-12 |
| 2013-03-31 | $2.79M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $3.39M 10-K · filed 2014-02-13 |
| 2012-06-30 | $117.00K 10-Q · filed 2012-07-25 |
| 2012-03-31 | $123.00K 10-Q · filed 2012-04-26 |
| 2011-12-31 | $116.00K 10-K · filed 2013-02-15 |
| 2011-09-30 | $149.00K 10-Q · filed 2011-10-27 |
| 2011-06-30 | $207.00K 10-Q · filed 2011-07-28 |
| 2010-12-31 | $1.13M 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |